Showing 1 posts of 1 posts found.
Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO